Westfield Capital Management Co. LP Has $135.64 Million Stake in Rhythm Pharmaceuticals, Inc. $RYTM

Westfield Capital Management Co. LP lifted its stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) by 18.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,267,158 shares of the company’s stock after buying an additional 198,154 shares during the quarter. Westfield Capital Management Co. LP owned about 1.90% of Rhythm Pharmaceuticals worth $135,637,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. EverSource Wealth Advisors LLC grew its position in Rhythm Pharmaceuticals by 303.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $28,000 after purchasing an additional 200 shares during the period. Smartleaf Asset Management LLC grew its position in Rhythm Pharmaceuticals by 97.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after purchasing an additional 141 shares during the period. Optiver Holding B.V. grew its position in Rhythm Pharmaceuticals by 65.2% in the 3rd quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock valued at $37,000 after purchasing an additional 144 shares during the period. SBI Securities Co. Ltd. grew its position in Rhythm Pharmaceuticals by 73.2% in the 4th quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock valued at $37,000 after purchasing an additional 145 shares during the period. Finally, GAMMA Investing LLC grew its position in Rhythm Pharmaceuticals by 48.6% in the 4th quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock valued at $39,000 after purchasing an additional 118 shares during the period.

Rhythm Pharmaceuticals Price Performance

RYTM opened at $87.61 on Friday. The company has a market capitalization of $6.00 billion, a price-to-earnings ratio of -27.99 and a beta of 1.91. The firm’s fifty day moving average price is $87.41 and its two-hundred day moving average price is $96.90. Rhythm Pharmaceuticals, Inc. has a 1 year low of $60.70 and a 1 year high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.83) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.03. The firm had revenue of $60.11 million for the quarter, compared to the consensus estimate of $55.78 million. Rhythm Pharmaceuticals had a negative net margin of 93.33% and a negative return on equity of 203.25%. The business’s revenue for the quarter was up 83.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.81) EPS. As a group, equities analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -3.18 EPS for the current year.

Wall Street Analysts Forecast Growth

RYTM has been the subject of several research reports. Zacks Research raised shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 17th. Needham & Company LLC reduced their price target on shares of Rhythm Pharmaceuticals from $139.00 to $130.00 and set a “buy” rating for the company in a research report on Tuesday, March 17th. Guggenheim lifted their price target on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, February 27th. Royal Bank Of Canada lifted their price target on shares of Rhythm Pharmaceuticals from $136.00 to $137.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $125.00 price target on shares of Rhythm Pharmaceuticals in a research report on Tuesday, March 3rd. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Rhythm Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $131.81.

Rhythm Pharmaceuticals Profile

Rhythm Pharmaceuticals, Inc is a clinical?stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin?4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.